Biotech Values

[DewDiligence]

RDHL -13% despite nominally positive phase-2 data in IBS-D:

https://finance.yahoo.com/news/redhill-biopharma-announces-positive-top-114101784.html

BEKINDA 12 mg Phase II study successfully met its primary endpoint, improving the primary efficacy outcome of stool consistency response (per FDA guidance definition) by an absolute difference of 19.4%, with 54.7% responders of subjects treated with BEKINDA (n=75) vs. 35.3% responders of the placebo subjects (n=51) (p = 0.05).

These top-line results compare favorably with previously reported efficacy outcome values for stool consistency response from two Phase III studies of Xifaxan (rifaximin) 550 mg (averaged absolute difference from Trial 1 and Trial 2 of 10.5%) and two Phase III studies of Viberzi 100 mg (eluxadoline) (averaged absolute difference of 13.5%).